EMA Authorised: Cibinqo (abrocitinib) — Pfizer Europe MA EEIG

View source ↗

Summary

The European Medicines Agency authorised Cibinqo (abrocitinib) for atopic dermatitis, with Pfizer Europe MA EEIG as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Cibinqo (abrocitinib)

Snippet

Status: Authorised. Therapeutic area: Dermatitis, Atopic. MAH: Pfizer Europe MA EEIG. Decision date: 23/06/2025